BACKGROUND: Because many Aboriginal Canadians had severe cases of pandemic (H1N1) 2009 influenza, they were given priority access to vaccine. However, it was not known if the single recommended dose would adequately protect people at high risk, prompting our study to assess responses to the vaccine among Aboriginal Canadians. METHODS: We enrolled First Nations and Métis adults aged 20-59 years in our prospective cohort study. Participants were given one 0.5-mL dose of ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmithKline Canada). Blood samples were taken at baseline and 21-28 days after vaccination. Paired sera were tested for hemagglutination-inhibiting antibodies at a reference laboratory. To assess vaccine safety, we monitored the injection site symptoms of each participant for seven days. We also monitored patients for general symptoms within 7 days of vaccination and any use of the health care system for 21-28 days after vaccination. RESULTS: We enrolled 138 participants in the study (95 First Nations, 43 Métis), 137 of whom provided all safety data and 136 of whom provided both blood samples. First Nations and Métis participants had similar characteristics, including high rates of chronic health conditions (74.4%-76.8%). Pre-existing antibody to the virus was detected in 34.3% of the participants, all of whom boosted strongly with vaccination (seroprotection rate [titre ≥ 40] 100%, geometric mean titre 531-667). Participants with no pre-existing antibody also responded well. Fifty-eight of 59 (98.3%) First Nations participants showed seroprotection and a geometric mean titre of 353.6; all 30 Métis participants with no pre-existing antibody showed seroprotection and a geometric mean titre of 376.2. Pain at the injection site and general symptoms frequently occurred but were short-lived and generally not severe, although three participants (2.2%) sought medical attention for general symptoms. INTERPRETATION: First Nations and Métis adults responded robustly to ASO3-adjuvanted pandemic (H1N1) 2009 vaccine. Virtually all participants showed protective titres, including those with chronic health conditions.
BACKGROUND: Because many Aboriginal Canadians had severe cases of pandemic (H1N1) 2009 influenza, they were given priority access to vaccine. However, it was not known if the single recommended dose would adequately protect people at high risk, prompting our study to assess responses to the vaccine among Aboriginal Canadians. METHODS: We enrolled First Nations and Métis adults aged 20-59 years in our prospective cohort study. Participants were given one 0.5-mL dose of ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmithKline Canada). Blood samples were taken at baseline and 21-28 days after vaccination. Paired sera were tested for hemagglutination-inhibiting antibodies at a reference laboratory. To assess vaccine safety, we monitored the injection site symptoms of each participant for seven days. We also monitored patients for general symptoms within 7 days of vaccination and any use of the health care system for 21-28 days after vaccination. RESULTS: We enrolled 138 participants in the study (95 First Nations, 43 Métis), 137 of whom provided all safety data and 136 of whom provided both blood samples. First Nations and Métis participants had similar characteristics, including high rates of chronic health conditions (74.4%-76.8%). Pre-existing antibody to the virus was detected in 34.3% of the participants, all of whom boosted strongly with vaccination (seroprotection rate [titre ≥ 40] 100%, geometric mean titre 531-667). Participants with no pre-existing antibody also responded well. Fifty-eight of 59 (98.3%) First Nations participants showed seroprotection and a geometric mean titre of 353.6; all 30 Métis participants with no pre-existing antibody showed seroprotection and a geometric mean titre of 376.2. Pain at the injection site and general symptoms frequently occurred but were short-lived and generally not severe, although three participants (2.2%) sought medical attention for general symptoms. INTERPRETATION: First Nations and Métis adults responded robustly to ASO3-adjuvanted pandemic (H1N1) 2009 vaccine. Virtually all participants showed protective titres, including those with chronic health conditions.
Authors: Joanne M Langley; Louise Frenette; Linda Ferguson; Dennis Riff; Eric Sheldon; George Risi; Casey Johnson; Ping Li; Richard Kenney; Bruce Innis; Louis Fries Journal: J Infect Dis Date: 2010-06-01 Impact factor: 5.226
Authors: Ryan Zarychanski; Tammy L Stuart; Anand Kumar; Steve Doucette; Lawrence Elliott; Joel Kettner; Frank Plummer Journal: CMAJ Date: 2010-01-21 Impact factor: 8.262
Authors: J McCarthy; S A Halperin; J A Bettinger; J M Langley; N S Crowcroft; S Deeks; J C Kwong; G De Serres; K Top; S McNeil; D W Scheifele Journal: Can Commun Dis Rep Date: 2015-02-20
Authors: Mariangela R Resende; Shahid Husain; Jonathan Gubbay; Lianne Singer; Edward Cole; Eberhard L Renner; Coleman Rotstein Journal: Can J Infect Dis Med Microbiol Date: 2013 Impact factor: 2.471
Authors: David W Scheifele; Marc Dionne; Brian J Ward; Curtis Cooper; Otto G Vanderkooi; Yan Li; Scott A Halperin Journal: Hum Vaccin Immunother Date: 2013-01 Impact factor: 3.452
Authors: Katya L Richardson; Michelle S Driedger; Nick J Pizzi; Jianhong Wu; Seyed M Moghadas Journal: BMC Public Health Date: 2012-12-20 Impact factor: 3.295
Authors: Luca Hensen; Thi H O Nguyen; Louise C Rowntree; Timon Damelang; Marios Koutsakos; Malet Aban; Aeron Hurt; Kim L Harland; Maria Auladell; Carolien E van de Sandt; Anngie Everitt; Cath Blacker; Damian A Oyong; Jessica R Loughland; Jessica R Webb; Bruce D Wines; P Mark Hogarth; Katie L Flanagan; Magdalena Plebanski; Adam Wheatley; Amy W Chung; Stephen J Kent; Adrian Miller; E Bridie Clemens; Peter C Doherty; Jane Nelson; Jane Davies; Steven Y C Tong; Katherine Kedzierska Journal: Proc Natl Acad Sci U S A Date: 2021-10-12 Impact factor: 11.205